Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study
International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1381-1388
DOI: 10.1007/s10147-026-03055-6 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 27.05.2026. Verfasst von Taisuke Tobe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017,…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Phenylurea Compounds, Antibodies, Monoclonal, Humanized, Pyridines. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pembrolizumab plus lenvatinib (Pem-Len) and nivolumab plus cabozantinib (Nivo-Cabo) are effective first-line regimens for metastatic renal cell carcinoma (RCC); however, real-world data directly comparing these regimens are limited. We conducted a retrospective analysis to compare their clinical outcomes in Japanese patients. METHODS: Patients with metastatic RCC who received Pem-Len or Nivo-Cabo as first-line systemic therapy at Kobe University Hospital and affiliated institutions between August 2018 and September 2025 were included. Clinicopathological characteristics and treatment outcomes were compared between the two groups. RESULTS: A total of 139 patients received Pem-Len and 97 received Nivo-Cabo. Patients in the Nivo-Cabo group were significantly older than those in the Pem-Len group. After propensity score matching for prognostic factors, progression-free survival (PFS) was significantly longer in the Pem-Len group than in the Nivo-Cabo group (not reached vs. 15.9 months, P = 0.019), but there was no significant difference in overall survival between the groups (not reached vs. 31.5 months, P = 0.308). The incidence of grade ≥ 3 adverse events was comparable between the groups (51.8% vs. 55.4%, P = 0.756). CONCLUSION: In this real-world analysis, Pem-Len was associated with longer PFS than Nivo-Cabo in patients with metastatic RCC, with comparable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
- Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. teishima@med.kobe-u.ac.jp.
Zitieren
APA
Tobe, T., Teishima, J., Mita, Y., Ueki, H., Shiraishi, Y., Wakita, N., Okamura, Y., Bando, Y., Suzuki, K., Hara, T., Terakawa, T., Chiba, K., Yao, A., & Miyake, H. (2026). Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International Journal of Clinical Oncology, 31(7), 1381-1388. https://doi.org/10.1007/s10147-026-03055-6
Vancouver
Tobe T, Teishima J, Mita Y, Ueki H, Shiraishi Y, Wakita N, et al. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International Journal of Clinical Oncology. 2026;31(7):1381-1388. doi:10.1007/s10147-026-03055-6
BibTeX
@article{Tobe2026,
author = {Tobe, Taisuke and Teishima, Jun and Mita, Yoshie and Ueki, Hideto and Shiraishi, Yusuke and Wakita, Naoto and Okamura, Yasuyoshi and Bando, Yukari and Suzuki, Kotaro and Hara, Takuto and Terakawa, Tomoaki and Chiba, Koji and Yao, Akihisa and Miyake, Hideaki},
title = {Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {7},
pages = {1381--1388},
doi = {10.1007/s10147-026-03055-6}
}
EUVIMED